Eli Lilly (LLY) stock climbs on gross margin beat, raised 2024 revenue outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Eli Lilly (LLY) PT Raised to $1,001 at BMO Capital
April 30, 2024 4:50 PM EDTBMO Capital analyst Evan David Seigerman raised the price target on Eli Lilly (NYSE: LLY) to $1,001.00 (from $900.00) while maintaining a Outperform rating.
The analyst comments "A high-quality earnings miss is one that 1) characterizes unprecedented demand; 2) justifies performance miss with supply constraints; 3) highlights efforts... More
Eli Lilly (LLY) PT Raised to $885 at Cantor Fitzgerald
April 30, 2024 2:01 PM EDTCantor Fitzgerald analyst Louise Chen raised the price target on Eli Lilly (NYSE: LLY) to $885.00 (from $815.00) while maintaining a Overweight rating.
The analyst comments "For 1Q24, US Zepbound revenue was $517MM vs. $363MM for FactSet. Zepbound is already annualizing at over... More
Weight-loss drug drives Eli Lilly to raise 2024 sales forecast by $2 billion
April 30, 2024 6:50 AM EDTBy Bhanvi Satija and Patrick Wingrove
(Reuters) -Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday, lifting its shares nearly 5%.
Lilly said it expects significant production increases in the second half of the year for its obesity treatment and related diabetes drug Mounjaro, for which most doses are in shortage due to high demand.
Skyrocketing demand for Mounjaro and Zepbound, both chemically known as tirzepatide, has propelled the Indianapolis-based drugmaker's market value above $700 billion - surpassing that of Tesla and Walmart.
... MoreEli Lilly & Co. (LLY) Tops Q1 EPS by 10c; Raises guidance
April 30, 2024 6:48 AM EDTEli Lilly & Co. (NYSE: LLY) reported Q1 EPS of $2.58, $0.10 better than the analyst estimate of $2.48. Revenue for the quarter came in at $8.77 billion versus the consensus estimate of $8.94 billion.
GUIDANCE:
Eli Lilly & Co. sees FY2024 EPS of $13.50-$14.00, versus the... More
